Latest Stocks: Minerva Neurosciences Inc (NERV) Upgraded at ValuEngine

Andrew Cummings
June 3, 2017

Minerva Neurosciences, Inc. (NERV) has a market capitalization of 367.05 Million which suggests the company is a huge company further suggesting that the shares of Minerva Neurosciences, Inc.

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now. and Minerva Neurosciences wasn't one of them! Zacks has also given Minerva Neurosciences an industry rank of 159 out of 265 based on the ratings given to related companies.

The average estimate of six analysts surveyed by Zacks Investment Research was for earnings of 23 cents per share. Finally, Jefferies Group LLC assumed coverage on shares of Minerva Neurosciences in a research report on Monday, March 6th.

The most recently updated ratings and price targets from brokers issued for Minerva Neurosciences, Inc (NERV) are included below. The company had a trading volume of 302,086 shares. The stock touched 52-week High of $15.84 on 09/23/16 and 52-week Low of $6.50 on 05/08/17.

Koss Corporation (NASDAQ:KOSS)'s market cap, the total dollar value of all of their outstanding shares, is 12.67m.

Minerva Neurosciences (NASDAQ:NERV) last posted its quarterly earnings results on Thursday, May 4th. The analysts estimated EPS for the higher end at -0.3 and lower end at -0.35 while the year ago reported earnings per share was 0. On average, equities analysts predict that Minerva Neurosciences will post ($1.50) EPS for the current fiscal year.

In other news, Director Marc D. Beer purchased 50,000 shares of the company's stock in a transaction on Monday, March 20th. The shares were purchased at an average price of $8.12 per share, for a total transaction of $406,000.00. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

A number of hedge funds have recently bought and sold shares of NERV. Bank of New York Mellon Corp increased its position in Minerva Neurosciences by 1.6% in the first quarter. Nexthera Capital LP increased its stake in shares of Minerva Neurosciences by 53.6% in the first quarter. Leading up to this report, we have seen a 10.74% rise in the stock price over the last 30 days and a -5.17% decline over the past 3 months. Handelsbanken Fonder AB increased its position in Minerva Neurosciences by 35.7% in the first quarter. Corporate insiders own 28.10% of the company's stock. As per Wednesday, March 9, the company rating was maintained by JMP Securities. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. & worldwide trademark and copyright legislation.

Minerva, after all, exited the most recent quarter with a mere $85.4 million in cash, and the company plans to accelerate its clinical activities in a big way on the back of this revised deal. The Firm is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases.

Minerva will retain its current rights to MIN-202 as adjunctive therapy for major depressive disorder (MDD), which include an exclusive license in the European Union, Switzerland, Liechtenstein, Iceland and Norway, with royalties payable by Minerva to Janssen, and royalties on sales payable by Janssen to Minerva elsewhere worldwide.

Other reports by iNewsToday